Bioniche Launches Animal Health Products

Bioniche Life Sciences Inc. (TSX:BNC, ASX:BNC), a technology-driven Canadian biopharmaceutical company announced that it has launched two new animal health products in Canada, namely, Immunocidin™ and Sin Susto™.

As quoted in the press release:

Immunocidin™is based on the Company’s proprietary mycobacterial cell wall technology, the same platform from which its Phase III product for human bladder cancer (Urocidin™) was derived. Immunocidin™is indicated as an immunotherapy for the intratumoral treatment of mixed mammary tumor and mammary adenocarcinoma in dogs. The product was launched in the U.S. in October, 2012.

Sin Susto™ – “without fear” – is an herbal calming product for dogs in chewable tablet form that was developed in collaboration with the University of Ottawa. The product is made from natural botanical ingredients and acts as an agonist at the Gamma-aminobutyric acid (GABA)_A receptor site. GABA is the primary inhibitory chemical messenger in the brain. Sin Susto™ has been proven safe and effective, is highly palatable, is non-habit-forming and non-psychotic, and does not act as a tranquilizer.

Click here to read the full Bioniche Life Sciences Inc. (TSX:BNC, ASX:BNC) press release.